Novo Nordisk | NVO - Selling And Administration Expenses


Novo Nordisk reported DKK2.54B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Bausch Health Companies USD 901M 88M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Drreddys Laboratories INR 14.47B 12.45B Mar/2026
Eli Lilly USD 3.43B 496M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Merck USD 2.89B 219M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Novo Nordisk DKK 2.54B 10.68B Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Perrigo USD 3.28B 3.02B Jun/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Sanofi EUR 2.63B 307M Jun/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Zoetis USD 588M 31M Mar/2026